Inhibition of platelet aggregation by a new agent, 5-(Z,E)-13,14-didehydro-20-methyl-carbo PGI2 (FCE 22509).
FCE (+)22509, a chemically stable carboprostacyclin analogue, inhibited in vitro ADP-induced platelet aggregation in rat platelet-rich plasma (PRP) (IC50 = 7.7 ng/ml). Subcutaneous administration of the drug, inhibited both ADP-induced platelet aggregation in rat PRP (ED50 = 0.26 mg/kg) and mortality of mice induced by collagen plus adrenaline (ED50 = 0.35 mg/kg). The compound had no such preventive effects when given orally.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D003094:Collagen / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology* / Q000031:analogs & derivatives; D066298:In Vitro Techniques; D007928:Lethal Dose 50; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D051381:Rats
D000244:Adenosine Diphosphate; C039192:13,14-didehydro-20-methylcarboprostacyclin; D003094:Collagen; D011464:Epoprostenol; D004837:Epinephrine